Patients were categorized by race (whites, blacks, others) and stage at diagnosis (localized, regional, distant or unknown) using Surveillance Epidemiology and End Results (SEER) Summary Stage 2000. In all, these 41 states provided 85% coverage of the US population in 2014. Maryland later submitted data for this study and was included (Supplementary Table S1). Missouri and Washington State were not included in these analyses because Missouri did not provide data on pancreatic cancer, and data from Washington State were only available for patients diagnosed up to December 31, 2008. In the US, 42 state registries provided data for CONCORD‐3. Overall, the study included data for over 37.5 million patients diagnosed with one of 18 cancers or groups of malignancies, including pancreatic cancer, worldwide.ĭata for CONCORD‐3 were provided by 322 population‐based cancer registries in 71 countries, 47 of which provided data with 100% coverage of the national population. The third cycle of the CONCORD program updated the global surveillance of trends in cancer survival to include patients diagnosed during 2000‐2014 and followed up to 31 December 2014. We examined data from the CONCORD‐3 study ( ) for 458,895 adults diagnosed with a primary, invasive, malignant tumor of the pancreas by anatomic site ) codes C250‐C254 and C257‐C259] and behavior (ICD‐O‐3 code 3). We aimed to examine the distribution and trends in net survival up to 5 years, stratified by race, stage at diagnosis, age and sex, for adults (15‐99 years) diagnosed with pancreatic cancer during 2001‐2014 in the US, overall and by US state. Pancreatic cancer survival in the US is slightly higher among women than among men, in younger than in older patients, and for patients with localized disease than for those with advanced disease. Other reports also suggest lower survival among blacks than whites, but these differences have not been seen in all studies. Five‐year survival was slightly higher in whites than in blacks during 2010‐2016, especially among men. The evidence on racial disparities in survival is less consistent. Pancreatic cancer incidence in the US is higher in African‐Americans (blacks) than in whites. In the CONCORD‐3 study, the age‐standardized 5‐year net survival generally ranged between 2.2% and 19.0% worldwide, with little improvement over time. Survival from pancreatic cancer is lower than for most other cancers. The only potentially curative treatment, radical surgery, combined with adjuvant chemotherapy, has been associated with a moderate improvement in survival. The main reason behind the poor prognosis is likely to be advanced‐stage disease at diagnosis due to the vague nature of symptoms and rapid tumor progression, and only about 10% are operable at diagnosis. Its incidence has been increasing by about 1% each year, and mortality by 0.3% per year. Pancreatic cancer is one of the most lethal cancers worldwide and the third most common cause of death from cancer in the United States (US).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |